Vivacelle Bio Enrolls First Patient in Phase 3 Trial of Hypovolemia Due to Septic Shock for Phospholipid Nanoparticle-Based VBI-S

KANSAS CITY, Mo., Sept. 3, 2024 /PRNewswire/ -- Vivacelle Bio, a late-stage biopharma company developing life-saving treatments for shock and trauma, today announced that it has enrolled the first patient in a Phase 3 trial for its lead therapeutic candidate, phospholipid nanoparticle-based VBI-S, to treat both absolute and relative hypovolemia due to septic shock and has initiated six trial sites. VBI-S is the first successful treatment for the overproduction of nitric oxide and to address both absolute and relative hypovolemia.

https://www.prnewswire.com/news-releases/vivacelle-bio-enrolls-first-patient-in-phase-3-trial-of-hypovolemia-due-to-septic-shock-for-phospholipid-nanoparticle-based-vbi-s-302235487.html?tc=eml_cleartime